Do elderly NSCLC stage IV patients benefit from chemotherapy as well as younger? An analysis from clinical practice date

Abstract

How to cite this article: Gironés R, López P, Chulvi R, Cañabate M. Do elderly NSCLC stage IV patients benefit from chemotherapy as well as younger? An analysis from clinical practice date. J Cancer Metasta Treat 2016;2:379-87. Aim:The aim of this study was to evaluate the efficacy of treatment related to age in metastatic non-small cell lung cancer (NSCLC). We compared young and elders (> 70) in the setting of a regional Spanish hospital. We hypothesized that elder benefit as much as younger patients from chemotherapy in stage IV NSCLC. The study was limited to performance status 0-2. Methods: Clinical and demographic characteristics were reviewed form medical records. Type of treatment was collected and compared, as well as benefit from treatment, in terms of overall survival. Results: 322 patients (162 young, 160 aged) Elderly patients received less active treatment (63% vs. 86%, P = 0.001). Elderly received less chemotherapy, less cisplatin-doublets, more carboplatin-combinations and monotherapy (P = 0.035). The benefits of treatment were similar, regardless of age. Smoking status demonstrated a prognosis impact for elder patients treated with chemotherapy. Those who remained active smokers had a lower overall survival in the aged group. In a multivariate analysis, the Eastern Cooperative Oncology Group, active treatment and non-smoking history were favorable prognostic factors for elder patients. Smoking had not impact on young patients. Conclusion: Elderly patients were undertreated in clinical practice. Treatment showed similar overall survival despite of age. The impact of smoking seems to be more significant in the elderly population. Key words:Non-small cell lung cancer, elderly, chemotherapy, overall survival, smoking habits, platinum-combinations ABSTRACTArticle history:

Geriatric assessment in clinical practice for patients with stage IV non-small-cell lung cancer: The Grup de Investigació I Divulgació Oncològica experience

“…Despite the clear benefits in terms of survival, most of older patients with advanced NSCLC are undertreated or do not receive chemotherapy (Beckett et al, ; Davidoff, Tang, Seal, & Edelman, ). Nevertheless, it has been demonstrated that older patients can benefit from first‐line chemotherapy (Gironés, López, Chulvi, & Cañabate, ) despite displaying greater toxicity than younger patients receiving the same regimens (Meoni, Cecere, Lucherini, & Costanzo, ). The main criteria used to select patients for oncological treatments are ECOG performance status (PS) assessments.…”